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ChIP-on-chipherpesvirus (KSHV) replication and transcription activator (RTA) encoded by
ORF50 is a lytic switch protein for viral reactivation from latency. The expression of RTA activates the
expression of downstream viral genes, and is necessary for triggering the full viral lytic program. Using
chromatin immunoprecipitation assay coupled with a KSHV whole-genome tiling microarray (ChIP-on-chip)
approach, we identiﬁed a set of 19 RTA binding sites in the KSHV genome in a KSHV-infected cell line BCBL-1.
These binding sites are located in the regions of promoters, introns, or exons of KSHV genes including ORF8,
ORFK4.1, ORFK5, PAN, ORF16, ORF29, ORF45, ORF50, ORFK8, ORFK10.1, ORF59, ORFK12, ORF71/72, ORFK14/
ORF74, and ORFK15, the two origins of lytic replication OriLyt-L and OriLyt-R, and the microRNA cluster. We
conﬁrmed these RTA binding sites by ChIP and quantitative real-time PCR. We further mapped the RTA
binding site in the ﬁrst intron of the ORFK15 gene, and determined that it is RTA-responsive. The ORFK15 RTA
binding sequence TTCCAGGAA TTCCTGGAA consists of a palindromic structure of two tandem repeats, of
which each itself is also an imperfect inverted repeat. Reporter assay and electrophoretic mobility shift assay
conﬁrmed the binding of the RTA protein to this sequence in vitro. Sequence alignment with other RTA
binding sites identiﬁed the RTA consensus binding motif as TTCCAGGAT(N)0–16TTCCTGGGA. Interestingly,
most of the identiﬁed RTA binding sites contain only half or part of this RTA binding motif. These results
suggest the complexity of RTA binding in vivo, and the involvement of other cellular or viral transcription
factors during RTA transactivation of target genes.
© 2009 Elsevier Inc. All rights reserved.IntroductionInfection by Kaposi's sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (HHV-8), is associated with the
development of Kaposi's sarcoma (Chang et al., 1994), primary
effusion lymphoma (PEL) (Cesarman et al., 1995) and a subset of
multicentric Castleman's diseases (Soulier et al., 1995). Like other
herpesviruses, the life cycle of KHSV consists of latent and lytic phases
that specify expression patterns of four classes of viral genes: latent,
immediate-early (IE), early, and late genes (Greene et al., 2007). The IE
genes are made immediately after primary infection or upon
reactivation from latency, and do not require de novo protein synthesis
(Deng et al., 2007). IE genes generally encode for regulatory proteins,, Greehey Children's Cancer
ience Center at San Antonio,
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ll rights reserved.and are critical for initiating viral transcription (Miller et al., 2007).
KSHV replication and transcription activator (RTA) is the gene product
of a major IE transcript transcribed from the ORF50 locus (Chen et al.,
2000; Lukac et al., 1999; Sun et al., 1998). The switch from KSHV latent
to lytic replication can be initiated by speciﬁc intracellular signals or
extracellular stimuli including chemical inducers such as 12-O-
tetradecanoyl phorbol-13 acetate (TPA) and sodium butyrate that
activate the expression of this key lytic switch protein. The expression
of RTA is necessary and sufﬁcient to trigger the full lytic program
resulting in the cascade expression of viral proteins, release of viral
progeny, and host cell death (Gradoville et al., 2000; Lukac et al., 1998,
1999; Sun et al., 1998; Xu et al., 2005).
RTA has been shown to activate the transcription of several
downstream viral genes, including ORFK1 (Bowser et al., 2002,
2006), ORFK2 (Deng et al., 2002; Song et al., 2003), ORFK3 (Rimessi
et al., 2001), ORFK5 (Haque et al., 2000), ORFK6 (Chang et al., 2005b),
PAN RNAs (Song et al., 2001, 2003, 2002), ORF35 (Masa et al., 2008),
ORF49 (Gonzalez et al., 2006), ORF50 itself (Chen et al., 2001; Deng et
al., 2000; Sakakibara et al., 2001), ORFK8 (Lukac et al., 2001; Seaman
and Quinlivan, 2003; Wang et al., 2004c; Wang and Yuan, 2007),
Fig. 1. Summary results of ChIP-on-chip. The peaks represented the relative enrichment of RTA binding signals over non-enriched input signals, along the KSHV genome and ORFs.
Circles indicated the RTA direct binding sites identiﬁed by the analysis. A total of 19 RTA direct binding sites were identiﬁed.
291J. Chen et al. / Virology 386 (2009) 290–302ORF57 (Byun et al., 2002; Song et al., 2003; Wang et al., 2003), ORFK9
(Chen et al., 2000; Ueda et al., 2002), ORF74 (Liang and Ganem, 2004),
ORFK12 (Song et al., 2003), and ORFK15 (Wong and Damania, 2006).
RTA activates its target genes through at least two mechanisms: direct
binding to the RTA-responsive elements (REs), or indirect binding to
other cellular factors (Chang et al., 2005b). For example, RTA directly
binds to the promoters of PAN RNAs (Song et al., 2002, 2003) and
ORFK12 (Chang et al., 2002) but does not bind to the ORF57 andORFK6
promoters (Chang et al., 2005b). The indirect binding of RTA to its REs
may be involved with the interaction of RTAwith RBP-Jkappa, a Notch
signal pathway transcription factor (Chang et al., 2005a; Liang et al.,
2002; Liang and Ganem, 2003, 2004). Other cellular transcriptional
factors that are involved in the activation of viral genes include AP-1
and OCT-1 for ORF50 itself (Pan et al., 2006; Sakakibara et al., 2001;
Wang et al., 2004a; Xie et al., 2008) and ORFK8 (Carroll et al., 2007), or
AP-1 for ORF35 (Masa et al., 2008), AP-1 or SP-1 for ORFK9 (Chen et al.,
2000; Ueda et al., 2002), and AP-1 for ORF57 (Byun et al., 2002; Wang
et al., 2004a). It has also been shown that RTA recruits CBP, the SWI/
SNF chromatin remodeling complex, and the TRAP/mediator co-
activator to its target promoters, and that such recruitment is essential
for the expression of RTA-dependent viral genes (Gwack et al., 2003).
The RTA protein is mainly encoded by ORF50 but obtains an
additional 60 amino acid (aa) to its N-terminal through a splicing
event that shifts its start codon across ORF49 (Chen et al., 2000; Sun et
al., 1998). The addition of the 60 aa is critical for its function as a viral
transactivator because a cloned protein from ORF50 itself neither
locates to the nuclei nor has any transactivation capacity (Chen et al.,
2000). The full-length functional RTA protein contains 691 aa, and is
predicted to have a molecular mass of 73.7 kDa. However, cellular RTAmigrated as a series of polypeptides with themajor ones at around 119
and 101 kDa, suggesting that RTA is post-translationally modiﬁed
(Chang and Miller, 2004; Lukac et al., 1999). RTA lacks signiﬁcant
homology with any cellular proteins but is a functional homolog of the
RTA proteins from Epstein–Barr virus (EBV), herpesvirus saimiri
(HVS) andmurine gammaherpesvirus 68 (MHV-68) (Wu et al., 2000).
The RTA protein consists of an N-terminal DNA binding domain, a
central dimerization domain, a C-terminal acidic activation domain,
and two nuclear localization signals (NLSs) (Chen et al., 2000; Lukac
et al., 1999). The DNA binding domain of RTA is located at the N-
terminus from aa 1 to 530. A deletion mutant of the activation domain
sequences, containing only the DNA binding domain (aa 1–530), has
been shown to be a dominant-negative mutant of RTA transactivation
(Lukac et al., 1999). This mutant maintains its DNA binding activity for
RTA REs but no longer activates the expression of downstream lytic
genes (Lukac et al., 1999, 2001; Song et al., 2001, 2003). This construct
binds to the RTA binding consensus sequence as a tetramer (Bu et al.,
2007). Using a puriﬁed fusion protein of thismutant GST-50ΔSTAD (aa
1 to 530) expressed in bacteria in an in vitroDNA binding assay named
systematic evolution of ligands by exponential enrichment assay
(SELEX), Ziegelbauer et al. (2006) identiﬁed a total of 18 RTA direct
binding sites in the KSHV genome including a binding site for the
ORF8 promoter; however they did not recover the known high-afﬁnity
PAN promoter site, nor the sites for the promoters of ORFK2, ORFK8,
ORF57, ORFK12 and ORF74. This may indicate that the bacterially
expressed GST-RTA fusion protein and the in vitro binding assay might
not be the ideal method for delineating the RTA binding sites in vivo.
To address this problem, we applied an in vivo ChIP-on-chip approach
coupled with a KSHV genome tiling array and a stable BCBL-1 cell line
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Table 1
RTA direct binding sites in the KSHV genome
Genomic location
by ChIP-on-chipa
Corresponding
gene
Location ChIP-qPCR Function References
8340–8580 ORF8 Promoter Yes Glycoprotein B (Ziegelbauer et al., 2006)
22860–23220 ORFK4.1 Promoter Yes Immediate-early gene In this study
23880–24180 OriLyt-L Yes Origin of lytic replication (Wang et al., 2004b, 2006)
27300–27540 ORFK5 Exon Yes vMIR2 In this study
28440–28740 PAN Promoter Yes Unknown (Song et al., 2001)
29640–30060 ORF16 Promoter Yes vBcl-2 In this study
51600–51960 ORF29 Intron Yes Immediate-early gene In this study
69000–69480 ORF45 Promoter Yes Immediate-early gene In this study
70980–71280 ORF50 Promoter Yes RTA In this study
74520–74940 ORFK8 Promoter Yes K-bZIP (Lukac et al., 1999; Wang et al., 2003)
92160–92520 ORFK10.1 Promoter Yes vIRF-3, or LANA2 In this study
96720–97020 ORF59 Promoter Yes DNA replication protein In this study
118680–118920 ORFK12 Promoter Yes Kaposin (Lukac et al., 1998; Song et al., 2003)
119940–120360 OriLyt-R Yes Origin of lytic replication (Wang et al., 2004b, 2006)
123360–123600 miRNA cluster Promoter Yes KSHV microRNAs In this study
126000–126240 ORF71/72 Promoter Yes vFLIP/vCyclin (Matsumura et al., 2005)
127380–127620 ORF74 Promoter Yes vGPCR In this study
3180–3540b ORFK15 Promoter Yes Membrane protein, EBV
LMP2A homolog
(Wong and Damania, 2006) and in
this study
Not identiﬁed ORFK2 No vIL-6 (Deng et al., 2002)
Not identiﬁed ORF57 No MTA (Duan et al., 2001; Liang et al., 2002;
Lukac et al., 1999)
a The number represents the nucleotide position in the KSHV genome (KSU75698) (Russo et al., 1996).
b The location related to ORFK15 is from sequence of KSU85269 (Nicholas et al., 1997).
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the RTA direct binding sites in the KSHV genome. A full set of RTA
direct binding sites in the KSHV genome including some that have not
been previously described were identiﬁed.
Results
Identiﬁcation of RTA direct binding sites in the KSHV genome
Previous studies have shown that RTA activates its downstream
genes by both direct and indirect bindings to the DNA sequences
(Chang et al., 2005b). To identify the RTA direct binding sites in the
KSHV genome, we generated a KSHV-infected stable BCBL-1 cell line,
BCBL-1-dRTA cell line, expressing the RTA DNA binding domain
tagged with 3FLAG epitope. Similar to the parental cell line, the
majority of the cells in this new cell line were latently infected by
KSHV but can be reactivated into lytic replication with chemical
inducer such as TPA or sodium butyrate. The use of RTA DNA binding
domain avoided the constitutive activation of viral lytic replication,
and hence cell death by RTA (Gradoville et al., 2000; Lukac et al.,
1998). This construct maintains the DNA-binding activity for the RTA
REs albeit it is no longer capable of activating the expression of lytic
genes (Lukac et al., 1999, 2001; Song et al., 2001, 2003). It also
reduces the confounding effects of cellular factors that cause indirect
RTA binding.
We carried out ChIP with TPA-induced BCBL-1-dRTA cells as
described in Materials and methods. The RTA-binding enriched DNA
was hybridized with a KSHV whole-genome tiling microarray. We
identiﬁed a set of RTA direct binding sites in the KSHV genome. Fig. 1
shows the genomic locations of the RTA binding sites. Peaks indicated
the relative enrichment of RTA-bound DNA (ratio of ChIP-enriched
DNA over non-enriched DNA). The selected criteria for each RTA
binding site were that it had at least ﬁve consecutive peaks, and each
peak had a minimum two-fold ChIP/Input ratio of enrichment.
Because the microarray has a 60-mer resolution, this represents aFig. 2. Detailed genomic locations of the identiﬁed RTA direct binding sites and their corres
genomic regions that had ﬁve consecutive peaks, each with a minimum two-fold ChIP/Inp
genome. Numbers indicated the genomic location of each peak in the KSHV genome (NC_0
region. The location of the RTA binding site in the ORFK15P promoter was based on the seqtotal of 300 bp in length for the RTA binding sites, which is comparable
to the original sheared immunoprecipitated DNA fragments. Based on
this criteria, we identiﬁed a total of 19 RTA binding sites in the KSHV
genome, which are located in the promoters, introns or exons of KSHV
genes including ORF8, ORFK4.1, ORFK5, PAN RNAs, ORF16, ORF29,
ORF45, ORF50, ORFK8, ORFK10.1, ORF59, ORFK12, ORF71/72, ORFK14/
ORF74, and ORFK15, the two origins of lytic replication (OriLyts)
OriLyt-L and OriLyt-R, and the microRNA cluster. The ﬁnding that RTA
binds OriLyts conﬁrms its crucial role in viral lytic replication. As a
major IE gene, RTA binds not only to the promoters of other IE genes
such as ORFK4.2, ORFK5, ORF29b, ORF45 and ORF48, as well as itself,
but also to early genes and a late gene ORF8. Interestingly, RTA
strongly binds to the latent gene cluster region (ORFK12 to ORF74),
and thus may serve as a transactivator for the expression of these
latent transcripts, including those of KSHV microRNAs. In fact, an
inducible promoter (LTi) and a constitutive promoter (LTc) immedi-
ately upstream of ORF73 have been described, and RTA activates LTi
but not LTc (Matsumura et al., 2005; Lan et al., 2005).
Fig. 2 shows the detailed locations of RTA direct binding sites in the
KSHV genome. There were two RTA binding sites located in the
ORFK12 promoter region. The location of RTA binding sites in the P
type ORFK15 promoter (K15P) was based on the KSHV sequence
Accession No: U85269 (Nicholas et al., 1997). Table 1 listed all the
identiﬁed RTA direct binding sites with the possible corresponding
target genes. Some of these genes such as PAN RNAs, ORFK8, ORFK12,
ORF74 and ORF8 have been previously identiﬁed to be the RTA direct
targets, and their RTA REs described (Lukac et al., 1998, 1999; Song et
al., 2001, 2003; Wang et al., 2003; Ziegelbauer et al., 2006). We also
identiﬁed several novel RTA direct binding sites in this study (Table 1).
To conﬁrm the putative RTA binding sites identiﬁed in the ChIP-on-
chip experiments, we performed ChIP-qPCR analyses. The primers
used in the qPCR are listed in Table 2. As shown in Fig. 3, ChIP-qPCR
conﬁrmed the RTA binding sites of ORF8, ORFK4.1, OriLyt-L, ORFK5,
PAN RNAs, ORF16, ORF29, ORF45, ORFK8, ORFK10.1, ORF59, ORFK12,
OriLyt-R, miRNAs, ORF71, ORF74, and ORFK15. RTA was not shown toponding target genes generated by ChIP-on-chip data. Putative RTA binding sites were
ut ratio of enrichment. A total 19 RTA direct binding sites were identiﬁed in the KSHV
03409) (Russo et al., 1996). Two RTA binding sites are located in the ORFK12 promoter
uence of KSU85269 (Nicholas et al., 1997).
Fig. 3. Quantitative real-time PCR (qPCR) of ChIP-enriched DNA. Speciﬁc primers
corresponding to the region of the identiﬁed RTA binding sites were designed, and used
in the qPCR (the sequences of these primers were listed on Table 2). Enrichments of
individual genomic regions were calculated as relative folds to that of β-actin gene,
which served as a negative control, together with CDK6.
Table 2
Primers used in the ChIP-qPCR assay
Name Positiona Sequences
ORF8 8341–8580 Forward: TTCTATAGCTTTGAGAATCA
Reverse: CGTTGTGAGTCCTGCGGGTT
ORFK4.1 22921–23100 Forward: TTAAAGGATCATAGTTCCCA
Reverse: AAAGGATTAGCGCATGCAAA
Ori-Lyt-L 24001–24180 Forward: GGGGGGGGGCTAGTGAGTCA
Reverse: GTAACAGTTGGTTAACCCGT
ORFK5 27327–27393 Forward: GGCGTGTACGACACGAGTGA
Reverse: GCGTACTGCTTGCCACGTT
PAN 28405–28670 Forward: GGTGACCCAACATAGTGATTCGG
Reverse: CAGTGCTAAACTGACTCAAGCTG
ORF16 29873–29919 Forward: GGGGTGTGGGATGGGGGTG
Reverse: CACACCCCCATCCCACACC
ORF29 51601–51840 Forward: AGGGGAGGAAAACCAACTTG
Reverse: ACGGCGCCCTCTGGCGGCGA
ORF45 68813–69486 Forward: TGAGCGGAGTTCTGTCAATG
Reverse: GGTTCTGTTAGCGGAAGTCAGAC
ORF50 71100–71280 Forward: TGGCATTTTGCCCGCATGTA
Reverse: CGAGCGTATTCTCAGAGGTC
ORFK8 74581–74930 Forward: CGGCACACTGTACCAGCTGC
Reverse: TTCCTCAATGACAGCTTCAT
ORFK10.1 92341–92520 Forward: GTACCGTCTGACATATGTGT
Reverse: TGGCAGCATACCTGAGTAAG
ORF59 96781–96960 Forward: CGCGCACACTGGGTGATCTG
Reverse: CCCCCTCTCATACACCGGCA
ORFK12 118764–119002 Forward: AGGGGGGTCGGTCTCCCCTCTTC
Reverse: CCGCCACTCCAGCCGTGTTAGCC
Ori-Lyt-R 121921–121980 Forward: CCGGCCGTCCTGGGCAGC
Reverse: GGGAGGAGGAAAAAGTAC
miRNA 123781–123838 Forward: GAGGAAAAAGGGGGAGAGGTG
Reverse: TCCTGGGGACTCTCCACAGG
ORF71/72 126061–126120 Forward: CTCATTGTCCTCATCATC
Reverse: GACGAGGAGGAGGACGAG
ORF74 127381–127560 Forward: ACAAGGGGGAGCTCTCAGAC
Reverse: GTGAGCCACCAGGACTTAAA
ORFK15b 3327–3923 Forward: CTATAAAAACAAATGTATGTGA
Reverse: GCGCCCTTCCCTTCCCCCATT
ORFK2 18180–18300 Forward: GCGCCTCCCGGTACAAGTCC
Reverse: GACCATTGGCGGGTAGAATC
ORF57 81721–82120 Forward: CGTTGCATTTACGCAACAAG
Reverse: TACCCTCTAGGATGCCCTTC
a The number represents the nucleotide position in the KSHV genome (KSU75698)
(Russo et al., 1996).
b ORFK15 primers were designed according to the sequence of KSU85269 (Nicholas
et al., 1997).
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these two genes may not be the direct targets of RTA as suggested by
previous studies (Byun et al., 2002; Chang et al., 2005b; Ziegelbauer
et al., 2006). However, it remains possible that the failure to detect the
RTA binding sites in the ORFK2 and ORF57 promoters was due to sub-
optimal condition in our analyses. As negative controls, RTA did not
bind to the promoter regions of β-actin and CDK6.
RTA binds to the latent gene cluster
We identiﬁed six RTA direct binding sites in the latent locus (Fig.
4). This region encodes at least 11 KSHV transcripts and all the 12
KSHV microRNAs in addition to OriLyt-R. These results indicate that
RTA might be heavily involved in regulating the expression of these
latent transcripts. Previous studies have identiﬁed a RTA RE between
the LTi and ORFK14 transcriptional start sites (Matsumura et al., 2005;
Staudt and Dittmer, 2006). The RTA binding site 1 falls in this region
(Fig. 4). Thus, this site might represent the reported putative RTA RE.
Further investigation is needed to conﬁrm the function of this site.
RTA activates a minimal TATA-promoter reporter containing the
upstream and intron region of both types of ORFK15 genes
We further investigated the transcriptional regulation of the
upstream and intron region of the ORFK15 gene by RTA, anddetermined the RTA direct binding sequences in this locus. KSHV
ORFK15 type P and M forms are highly diverged with less than 30%
amino acid homology to one another (Choi et al., 2000; Glenn et al.,
1999; Poole et al., 1999). Our ChIP-on-chip data indicated that RTA
binds to the upstream of the ORFK15P gene from the BCBL-1 cells
(Fig. 1). We constructed ORFK15 upstream/intron-luciferase reporters
from BCBL-1 (type P) and BC-3 (type M) cells (Fig. 5A). The ORFK15
gene is located next to the right TR of the KSHV genome, and is tran-
scribed in a leftward orientation (Fig. 5A). Reporter assay indicated
that RTA activates both constructs (Fig. 5B) and the transactivation of
these two genes by RTA was dose-dependent (Figs. 5C and D).
Identiﬁcation of a RTA RE in the ORFK15 upstream/intron region
To determine the location of RTA RE in the ORFK15 upstream/
intron region, the K15P reporter construct was further used to
generate a series of deletion mutants (Figs. 6A and B). Surprisingly,
luciferase reporter assay showed that all the deletion mutants were
responsive to RTA transactivation (Fig. 6C), indicating that the RTA RE
must exist within the minimal sequence of D6, a 106-bp deletion
mutant located in the ﬁrst ORFK15 intron. Next, we generated ﬁve
overlapping luciferase reporter clones covering this 106-bp sequence
region by PCR-based cloning strategy (Fig. 7A). Each clone is 30 bp in
length with 10 bp overlapping sequence. Reporter assay indicated
that, similar to the full-length (600-bp) and D6 (106-bp) constructs,
the RE1 construct was responsive to RTA transactivation (Fig. 7B). The
sequence of RE1 is shown in Fig. 7C. Computational analysis of this
sequence revealed a palindromic structure with two tandem-repeats
(bold sequence in Fig. 7C).
Identiﬁcation of a RTA direct binding site in vitro
To test whether RTA could bind to the RE1 sequence in vitro, we
performed a competitive EMSA assay (Fig. 8), using AP-1 consensus
sequence, RE1, and the putative RTA binding sequence (RE11) as
probes. We found that all the labeled probes could form complexes
with nuclear proteins from the 293T cells transiently transfected with
the p3FLAG-RTA plasmid. However, the DNA–protein complex
detected by the AP-1 probe could not be eliminated by addition of
excess unlabeled RE1 (lane1) and RE2 (lane 2) probes, indicating that
the AP-1–protein complex was not related to the RE1 and RE2
sequences. In contrast, the DNA–protein complex formed by RE1
(lanes 4–6) or RE11 (lane 7–9) probes could be eliminated by addition
of excess unlabeled RE1 (lanes 4 and 7) but not RE2 (lanes 5 and 8). To
examine whether this DNA–protein complex is due to the RTA
binding, we performed a supershift assay with the RE1 probe and an
Fig. 4. RTA strongly binds to the latent locus in the KSHV genome. ChIP-on-chip data were shown along with genes and genomic locations. The location of the right side origin of lytic
replication (OriLyt-R) and the microRNA cluster were indicated. Possible transcripts in this region were also shown.
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formed by the RE1 probe could be eliminated by excess unlabeled RE1
(lane 4) and RE11 (lane 6) but not by AP1 (lane 3) and RE2 (lane 5).
Additionally, this DNA–protein complex could be supershifted by
speciﬁc antibodies against FLAG (lane 7) and RTA (lane 8),
demonstrating that RTA speciﬁcally bound to the RE1 region in vitro
(Fig. 8C).
RTA binds to a sequence with a palindrome structure
To deﬁne the RTA RE sequence, we tested the RTA binding
efﬁciency with several known RTA REs from previous reports (Fig. 9).
Fig. 9B indicated that the complex formed by the RE1 probe could be
eliminated by the excess amount of unlabeled RE11 (lane 3) and RE12
(lane 4), as well as by the known RTA REs previously identiﬁed in the
promoters of ORFK2 (lane 8), ORFK8 (lane 9), PAN RNAs (lane 10),
ORFK12 (lane 11), and partially ORF57 (lane 12), but not by the AP1
consensus sequence (lane 2) and RE2 (lane 5). Antibody against FLAG
supershifted this complex (lane 7), though antibody against RTA only
formed a weak supershift band (lane 6). The fact that RTA binds to
ORFK2 and ORF57 promoter in vitro in EMSA (Fig. 9B) but no in vivo in
ChIP-on-chip (Figs. 1 and 2) indicated that in vitro EMSA assay might
not be ideal for examining the RTA direct binding sites.
Determination of the RTA binding sequence
Using Motif Discovery scan (MDscan) (Liu et al., 2002), we
determined the RTA binding sequence in the ORFK15 region as a
palindromic element with two tandem-repeats TTCCAGGAATTCCTGGAA (Fig. 9C). This two tandem-repeats structure is similar
to that of p53 consensus binding elements (el-Deiry et al., 1992), and
may indicate the binding of RTA to DNA as a tetramer (Bu et al., 2007).
Detailed analysis of other RTA binding sites identiﬁed the RTA
consensus binding motif as TTCCAGGAT(N)0–16TTCCTGGGA, which
contains two imperfect inverted tandem-repeats (Fig. 10A). The gap
that separates the tandem repeats also varies with different RTA
binding sites ranging from 0 to 16 bp. Interestingly, some of the
tandem-repeats in the RTA REs contain only half of the tandem-repeat
sequence (TTCC) (Fig. 10A). We further examined the sequences of
other RTA binding sites that failed in the initial alignment analysis. The
majority of these sites with the exception of RTA and ORFK5 identiﬁed
in this study also contain at least half of the tandem-repeat sequence
(Fig. 10B).
Discussion
RTA is a critical switch gene for viral reactivation from latency.
Delineation of the genome-wide locations of RTA binding sites in the
KSHV genome in vivo is important for the comprehensive under-
standing of viral reactivation and gene regulation. However, this has
turned out to be a difﬁcult task because of the weak binding of RTA to
its targets in vivo and the activation of full lytic replication and cell
death following overexpression of RTA. Using a novel strategy, we
were able to determine the full set of RTA direct binding sites in the
KSHV genome. We designed our ChIP-on-chip experiments based on
several considerations. The most important factor is the quality of the
antibody used for the immunoprecipitation. Transcription factors
generally are expressed at low levels in the living cells, and have
Fig. 5. RTA activates a minimal TATA-promoter reporter containing the upstream/intron sequence of both types of the ORFK15 gene. (A) Structure of the ORFK15 gene from BCBL-1
(type P) or BC-3 (type M) cells. The upstream/intron region of the ORFK15 gene (from TR to the second exon) was PCR ampliﬁed from BCBL-1 cells as a 600 bp fragment or from BC-3
cells as a 1000 bp fragment, and cloned into the pTAL-luc vector containing a minimal TATA-promoter as reporter constructs, K15P and K15M, respectively. (B) Luciferase reporter
assay with the ORFK15 upstream/intron constructs in response to RTA activation in 293T cells. Transfection efﬁciencies were normalized by co-transfection with a control plasmid
pCMV-β-gal. Relative luciferase activities of K15P or K15M reporter constructs in response to RTA (pcDNA–RTA) were shown in fold compared to that of an empty vector control
(pcDNA3.1). (C and D) Activation of the ORFK15 upstream/intron-luciferase reporters by RTA is dose-dependent. Both of K15P (C) and K15M (D) upstream/intron reporter
constructs were activated by RTA in a dose-dependent manner. All the experiments were independently carried out three times, each with three repeats. Results were the averages
plus standard deviations from one representative experiment.
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Fig. 6. (A) Schematic illustration of the ORFK15P reporter and its serial deletion mutants in relative to the ORFK15 upstream sequence and exons. The 5′ ends of these constructs
indicate the positions in relative to the ORFK15 transcription start site. (B) Colony-PCR of deletion mutant constructs. Appropriate deletion clones were obtained by colony-PCR and
selected based on sizes and DNA sequencing. (C) Transactivation of the ORFK15P upstream/intron reporter and its mutant constructs by RTA in 293T cells. The indicated deletion
mutants were co-transfected with the RTA expression construct (pcDNA–RTA) or empty vector (pcDNA3.1). Luciferase intensities were normalized by co-transfectionwith pCMV-β-
gal, and calculated as fold increase over that of pTAL-luc vector. All the experiments were independently carried out three times, each with three repeats. Results were the averages
plus standard deviations from one representative experiment.
297J. Chen et al. / Virology 386 (2009) 290–302weaker afﬁnities for DNA than histone proteins. Therefore, ChIP
application of transcription factors is particularly demanding since the
antibodymust be capable of recognizing the native protein as part of a
cross-linked DNA–protein complex. We have tested both monoclonal
and polyclonal antibodies against RTA from different groups (Okuno
et al., 2002; Yang and Wood, 2007) as well as our own laboratory.
Although these antibodies work well for other applications, they failed
to enrich RTA–DNA complex sufﬁciently, and consequently, the signal-
to-noise ratios were too low to make any meaningful direct
microarray analysis of the RTA binding sites (data not shown).
Among all the systems that we have tested, triple FLAG epitope and
the corresponding anti-FLAG M2 antibody is the most sensitive
antigen-antibody detection system. Detection of fusion proteins
containing the 3×FLAG is 20–200 times more sensitive than other
tags such as c-myc, 6×His, GST or HA, and therefore, is ideal for the
ChIP assays of proteins expressed at low levels in mammalian cells
(Wu and Chiang, 2002). In this report, a stable BCBL-1 cell line
expressing the DNA binding domain of RTA tagged with a 3FLAG tag
was used in the ChIP-on-chip assay.
The advantages for using the DNA binding domain alone to identify
the RTA direct binding sites are as follows: 1) Unlike structure
proteins, constitutive expression of RTA leads to full viral lytic
expression and cell death (Gradoville et al., 2000; Lukac et al.,
1998), therefore, prevents the harvest of sufﬁcient RTA–DNA
complexes for the microarray analysis. 2) Previous reports have
indicated that the RTA construct containing only the DNA binding
domain maintains the DNA binding activity for the RTA REs albeit it isno longer capable of activating the expression of lytic genes (Lukac et
al., 1999, 2001; Song et al., 2001, 2003), and therefore, can be used to
establish a stable RTA expressing cell line. In fact, this construct has
been used for studying the RTA binding sites by other groups (Bu et al.,
2007; Ziegelbauer et al., 2006). 3) The use of DNA binding domain
alone can reduce the confounding effects of cellular factors that cause
indirect RTA binding.
While the use of RTA–DNA binding domain is necessary to
circumvent some of the technical difﬁculties associated with the
ChIP assay, it also introduces additional confounding factors. 1) The
RTA–DNA binding domain does not fully reﬂect the action of the full-
length molecule, which could lead to under- or over-representation of
the RTA binding sites. 2) Although less likely than the full-length
molecule, the RTA–DNA binding domain could still bind to the RTA REs
by partnering with other viral and cellular proteins. 3) The protein
expression level in the stable expression condition might not reﬂect
all the in vivo situations. Indeed, we have observed a wide dynamic
range of protein expression levels of the wild-type RTA following lytic
induction over time (data not shown). Furthermore, at a given time
point following lytic induction, the protein expression levels of the
wild-type RTA also vary vastly at the individual cell level. Obviously, it
is not possible to examine the RTA–DNA binding targets at all
expression levels in vivo even if the ChIP approach works with the
endogenous protein. Nevertheless, the stable expression approach at
least captures some in vivo conditions, most likely at high RTA
expression levels. Thus, when analyzing results obtained by different
approaches including the ChIP assay that we used, it is necessary to
Fig. 7. (A) Schematic illustration of serial overlapped RTA RE reporter constructs within
the ﬁrst intron of the ORFK15P gene. (B) Transactivation of the RTA RE reporter
constructs by RTA in 293T cells. The indicated deletion mutants were co-transfected
with the RTA expression construct (pcDNA–RTA) or empty vector (pcDNA3.1).
Luciferase intensities were normalized by co-transfection with pCMV-β-gal, and
calculated as fold increase over that of the pTAL-luc vector. All the experiments were
independently carried out three times, each with three repeats. Results were the
averages plus standard deviations from one representative experiment. (C) The
identiﬁed minimal RTA RE sequence contains a palindromic structure (bold).
Fig. 8. Detection of DNA–protein complex of the RTA target sequence in the ORFK15P
intron by electrophoretic mobility shift assay (EMSA). (A) Oligonucleotide sequences of
probes used in the assay. The palindromic structure of the RTA RE is shown in bold. (B)
EMSA results with probes AP-1 (lanes 1–3), RE1 (lanes 4–6) and RE11 (lanes 7–9), and
nuclear extracts from 293T transiently transfected with p3FLAG-RTA. Unlabeled oligos
(RE1 and RE2) were used in excess amount (50 fold) as competitors in lanes 1, 4, and 7
(RE1) and lanes 2, 5, 8 (RE2), respectively. Reactions without any competitors were also
carried out (lanes 3, 6, and 9). A speciﬁc DNA–protein complex was detected with
probes RE1 and RE11. The DNA–protein complexes formed by probes RE1 and RE11 can
be speciﬁcally inhibited by addition of excess amount of cold RE1 oligo (lanes 4 and 7)
but not by cold RE2 oligo (lanes 5 and 8). (C) EMSA results with probe RE1 and nuclear
extracts from 293T cells transiently transfected with the p3FLAG-RTA plasmid.
Unlabeled oligos (AP-1, RE1, RE11, and RE2) were used in excess amount (50 fold) as
competitors in lanes 3–6. A reactionwithout any competitors was also carried out (lane
2). Lane 1 contained only the probe without any nuclear extracts. Supershift assay was
performed with antibodies against FLAG (lane 7) and RTA (lane 8), respectively. The
numbers on the lanes represent the relative signals of the protein–DNA complexes (B
and C).
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discrepancies between the RTA REs identiﬁed in this study with those
identiﬁed by other approaches.
In a previous report, Ziegelbauer et al. (2006) identiﬁed a total of
18 RTA binding sites using puriﬁed GST-50ΔSTAD fusion protein
expressed in bacteria and an in vitro SELEX assay. We performed our
ChIP-on-chip experiments and data analysis without previous knowl-
edge of this dataset in order to avoid any bias in analyzing our results.
Of 18 RTA binding sites identiﬁed by Ziegelbauer et al., 10 (56%) were
detected in our ChIP-on-chip assay. Interestingly, both studies failed to
conﬁrm the binding of RTA to the promoter regions of ORFK2 and
ORF57, suggesting that these two genes might not be the direct targets
of RTA in vivo, albeit both promoters contains two halves of the
tandem-repeats of the consensus RTA binding motif (Fig. 10A), and
RTA bindings to these promoters were detectable in vitro (Fig. 9). In
addition to the RTA binding sites identiﬁed by Ziegelbauer et al., we
identiﬁed several novel binding sites, including those in the promoter
regions of ORFK4.1, ORF16, ORF45, the miRNA cluster, ORF74, and
ORFK15, as well as the well-deﬁned RTA binding sites in the PAN and
ORFK12 promoters. The discrepancies of these two datasets of RTA
direct binding sites might indicate the fundamental differences
between the in vitro and in vivo binding sites of transcription factors.
A recent study examined the RTA direct targets in a reporter assay
through conditional induction of RTA nuclear localization in the
presence of cycloheximide, and identiﬁed 8 downstream genes
activated by RTA, including PAN RNAs, ORF57, ORF56, ORFK2, ORF37,
ORFK14, ORFK9, and ORF52 (Bu et al., 2008), of which only the sites of
PAN RNAs and ORFK14 were identiﬁed in our study. However, it
remains possible that RTA could activate its downstream genes by
partneringwith other preexisting viral and cellular nuclear proteins in
this system, even in the presence of cycloheximide.
Previous studies have identiﬁed two OriLyts in the KSHV genome
(AuCoin et al., 2002, 2004; Lin et al., 2003). Both RTA and ORFK8,along with other cellular factors are required for the origin-
dependent DNA replication (Wang et al., 2004c, 2006, 2008). Our
data clearly indicated that RTA intensively bound to both OriLyts
(Figs. 1–3), thus supporting a pivotal role of RTA in viral DNA
Fig. 9. Binding or RTA to its target sites detected by electrophoretic mobility shift assay
(EMSA). (A) Oligonucleotide sequences used in the assay. The palindromic structure of
the RTA RE is shown in bold. (B) EMSA results with probes RE1 and nuclear extracts
from 293T cells transiently transfected with the p3FLAG-RTA plasmid. Unlabeled oligos
(AP-1, RE11, RE12, and RE2) and oligos from known RTA REs (ORFK2, ORFK8, PAN,
ORFK12, and ORF57) were used in excess amount (50-fold) as competitors in lanes 2–5,
and lanes 8–12, respectively. A reaction without any competitors was also carried out
(lane 1). Supershift assay was performed with antibodies against RTA (lane 6) and FLAG
(lane 7), respectively. (C) The RTA RE sequence identiﬁed in this study. A typical
palindromic sequence with two tandem repeats was shown.
299J. Chen et al. / Virology 386 (2009) 290–302replication during viral reactivation. The identiﬁcation of RTA
binding sites on other IE genes such as ORFK4.1, ORFK5, ORF29b,
ORF45, ORF48, and ORF50 itself further support the conclusion that
RTA is a true lytic switch gene of KSHV.
KSHV ORFK15 is expressed at both viral latent and lytic phases as
complex transcription patterns (Choi et al., 2000; Glenn et al., 1999;
Poole et al., 1999). Our study identiﬁed the RTA binding site in the ﬁrst
intron of the ORFK15 gene from BCBL-1 cells (type P). Nevertheless,
we could not rule out the possibility that there were additional RTA
REs located in the ORFK15 promoter region as reported in another
study (Wong and Damania, 2006). Through the binding to the ﬁrst
intron, RTA likely contributes to the transcription regulation of the
ORFK15 gene. Further investigation is undergoing to determine the
role of RTA in regulating the differential expression patterns of various
ORFK15 transcripts.
RTA activates its downstream genes through two distinct mechan-
isms: direct binding through RTA REs and indirect binding through
cellular cofactors. In this study, we identiﬁed a total of 19 RTA direct
binding sites in the KSHV genome, and deﬁned the RTA binding
sequence in the ﬁrst intron of ORFK15 gene as a palindromic element
with two tandem repeats (TTCCAGGAA TTCCTGGAA). Sequencealignment with other RTA REs identiﬁed the RTA consensus binding
motif as TTCCAGGAT(N)0–16TTCCTGGGA, which contains two imper-
fect inverted tandem repeats (Fig. 10A). Some RTA REs contain only
one, two halves, or even just half of the tandem repeat sequence
(TTCC) (Fig. 10B). The gap that separates the tandem repeats also has
large variations, ranging from 0 to 16 bp. These results indicate that
RTA might bind to the majority of the target genes in more
complicated manners, most likely, through recruitments of other
cellular or viral transcription factors.
Materials and methods
Antibodies
Polyclonal antibody against RTA was a gift from Dr. Charles Wood
(Yang andWood, 2007). Mouse monoclonal antibody against RTAwas
a gift from Dr. Koichi Yamanishi (Okuno et al., 2002). An anti-FLAGM2
antibody and the corresponding agarose beads used in immunopre-
cipitation were purchased from Sigma Life Science (St. Louis, MO).
Plasmids
p3FLAG is a vector for stable mammalian expression of protein
fused with a triple FLAG epitope on the N-terminal (Chen, 2006). The
full-length RTA (691 aa) expression vector (pcDNA-50Full) was
previously described (Chen et al., 2001). A full-length RTA with the
3FLAG tag (p3FLAG-RTA) was constructed in this study. A C-terminal-
truncated RTA–DNA-binding domain (aa 1–390) tagged with the
3FLAG epitope (p3FLAG-dRTA) was constructed for the ChIP-on-chip
assay by PCR ampliﬁcation using the pcDNA-50Full DNA as a template,
and primers RTA-NF (5′GACAAGCTAGCGCAAGATGACAAGGGTAA3′)
and RTA-XR (5′ TTGTTCTAGAGCAGGAGTGGACGCTGAC3′), which
contain the NheI and XbaI sites (underlined).
Theminimal TATA-promoter reporter plasmid pTAL-luc containing
the ﬁreﬂy luciferase gene (ClonTech Laboratories, Inc., Mountain View,
CA) was used for the construction of the ORFK15 upstream/intron or
RTA RE reporter constructs. Serial deletion mutants of the ORFK15
upstream/intron reporter construct were generated using a deletion
kit for kilo-sequences according to the instructions of the kit (Takara,
Madison, MI). All constructs were sequenced and conﬁrmed.
Cell lines and cell culture
Human PEL cell line, BCBL-1, was grown in RPMI1640 supplemen-
tedwith 10% fetal bovine serum (FBS). Human embryonic kidney 293T
cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM)
with 10% FBS. A stable BCBL-1 cell line expressing the RTA–DNA
binding domain tagged with 3FLAG epitope was established by
transfection of BCBL-1 cells with the plasmid p3FLAG-dRTA followed
by selection in 800 μg/ml G418 (Sigma) and single cell cloning. The
resulting BCBL-1-dRTA cell line was shown to express the 3FLAG-RTA
fusion protein by immunoblotting assay (data not shown). When
necessary, cells were treated with 25 ng/ml of TPA (Sigma) to induce
viral lytic replication.
KSHV whole-genome tiling array
Custom-designed KSHV whole-genome tiling microarray, which
contains a total of 10,260 probes of 60-mer oligonucleotides, was
designedmainly based on the type M BC-1 KSHV sequence (Accession
No.: NC_003409) (Russo et al., 1996) and synthesized by Agilent
Technologies (Santa Clara, CA). This DNA microarray containing 4 full
sets of KSHV genome including the terminal repeat (TR) covers the
sense and complimentary DNA strands with overlapping probes. In
addition, this array contains partial KSHV type P sequence (Accession
No: U85269) (Nicholas et al., 1997), representative ORFK1 sequences
Fig. 10. Alignment and generation of consensus RTA binding sequence. (A) Consensus RTA binding motif derived from RTA binding sequences generated in this study (ORFK8,
ORFK12, miRNA, ORF16, OriLyt-L, PAN RNAs, and ORFK15) and those of published data (ORFK2 and ORF57). (B) Partial tandem repeat in other RTA binding sequences generated in
this study (ORF8, ORFK4.1, ORF29, ORF45, OriLyt-R, ORF74, ORF71/72, ORFK10.1 and ORF59). RTA binding elements were analyzed with the Motif Alignment & Search Tool (http://
meme.sdsc.edu/meme/mast.html).
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sets of KSHV microRNAs, consensus RTA binding sequences (PAN,
ORF57, ORFK8, etc.), and sequences from cellular house-keeping genes
serving as negative controls (Vandesompele et al., 2002).
ChIP
BCBL-1-dRTA cells were induced with 25 ng/ml of TPA for 6 h to
initiate KSHV lytic replication. A total of 5×108 cells were collected,
washed three times with PBS, and cross-linked in 45 ml of PBS
containing 1% formaldehyde for 10 min at room temperature with
occasional inversion. The cross-linking reaction was quenched with
5 ml of 1.25 M glycine, and the cells were washed twice in ice-cold
PBS. The cells were then suspended in 5 ml of ice-cold hypotonic
buffer containing 10 mM Hepes at pH 7.9, 10 mM KCl, 1.5 mM MgCl2,
0.5 mM DTT. The cells were passed through a 21-gauge needle 10
times followed by incubation on ice for another 30 min to disrupt
cell membranes. Nuclei were collected by spinning at 10,000 ×g for
8 s, washed once in the hypotonic buffer, and re-suspended in 5 ml
of ChIP lysis buffer containing 50 mM Hepes at pH 7.9, 150 mM NaCl,
1 mM EDTA, 1% Triton X-100 and 1xPIC (Protease inhibitor cocktails,
Sigma). After incubation on ice for 30 min, the nuclear lysate was
sonicated on ice for 10 min with a 10-sec burst/50-sec pause cycle to
generate sheared DNA with an average size of 300 bp. The
suspension was then centrifuged at 12,000 ×g for 10 min at 4 °C,
and the supernatant volume was increased to 10 ml with lysis buffer.
The FLAG-tagged protein–DNA complexes were immunoprecipitated
by incubating with 400 μl of anti-FLAG M2 afﬁnity agarose beads
(Sigma) overnight at 4 °C, and then centrifuging for 5 s at 10,000 ×g.
The supernatant was kept as non-enriched control DNA. The agarose
beads were washed three times sequentially in the ChIP lysis buffer,
ChIP high-salt buffer (50 mM Hepes at pH 7.9, 500 mM NaCl, 1 mM
EDTA, 1% Triton X-100), ChIP wash buffer (50 mM Hepes at pH 7.9,250 mM LiCl, 1 mM EDTA, 1% Triton X-100), and then TE buffer
(10 mM Tris at pH 8.0, 1 mM EDTA), all containing 1xPIC. The DNA–
protein complexes were eluted from the beads by adding 400 μl of
ChIP elution buffer containing 50 mM Tris at pH 8.0, 10 mM EDTA, 1%
SDS into the beads followed by incubation at 65 °C overnight with
agitation. ChIP elution buffer at 400 μl was also added to 100 μl of
the non-enriched DNA control. Both the enriched (immunoprecipi-
tated) and non-enriched DNA samples were treated with 5 μl of
RNase A at 10 mg/ml for 1 h at 37 °C, and then with 20 μl of
proteinase K at 20 mg/ml for 1 h at 50 °C. The DNA samples were
then extracted twice with phenol/chloroform, once with chloroform,
precipitated with ethanol, and dissolved in 100 μl of TE.
Microarray hybridization and data analysis
Microarray probe labeling, hybridization, and scanning were
performed according to Agilent's protocol for mammalian ChIP-on-
chip (Version 9.0) with some modiﬁcations. Brieﬂy, ChIP-enriched or
non-enriched DNA sample (5 μg each) was labeled directly with either
Cy5-dCTP or Cy3-dCTP (GE Healthcare, Piscataway, NJ) without the
PCR ampliﬁcation step to reduce any potential ampliﬁcation bias.
Probe labeling was performed using the BioPrime Array CGH Genomic
Labeling Kit (Invitrogen, Carlsbad, CA) in 75-μl reactions. The puriﬁed
labeled sampleswere thenmixed, andmicroarray hybridizationswere
performed at 65 °C for 2 days with gentle agitation in a SureHyb
chamber and hybridization oven (Agilent). The hybridized arrays
were then washed and scanned on a GenePix 4000A scanner
(Agilent), and the images were analyzed with the Feature Extraction
software version 9.1 (Agilent).
For data analysis, we assumed that all short chromatin intervals
were subjected to a uniform probability of shearing during the
sonication step, and that these short chromatin intervals were
independent of each other. Since the array had a 60-mer resolution,
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a minimum of ﬁve consecutive peaks. Each peak was deﬁned as a
minimum of two-fold ChIP/Input ratio of enrichment. The length of
ﬁve consecutive peaks is 300 bp, which is comparable to the original
sheared immunoprecipitated DNA fragments.
Conventional ChIP analysis with quantitative real-time PCR (ChIP-qPCR)
BCBL-1-dRTA cells were treated with 25 ng/ml of TPA for 6 h
before cross-linking and immunoprecipitated with the anti-FLAG M2
afﬁnity agarose beads. ChIP-enriched DNAwas dissolved in 30 μl of TE,
and 2 μl each of ChIP-enriched and non-enriched DNA control were
ampliﬁed by qPCR using the 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA). Primers used for the qPCR, some of which
have been described in a previous study (Yoo et al., 2005), are listed in
Table 2.
Electrophoretic mobility shift assay (EMSA)
293T cells (107) transiently transfected with the p3FLAG-RTA
plasmid were collected by low-speed centrifugation, washed three
times with cold PBS, suspended in 1 ml of buffer A containing 10 mM
Hepes at pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and passed
10 times through a 27 1/2 gauge needle. Nuclei were collected by
spinning at 10,000 ×g for 8 s, washed once with the buffer A, and
suspended in 200 μl of cold buffer C containing 20 mM Hepes at pH
7.9, 25% glycerol, 420 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
DTT, and 0.5 mM PMSF, and incubated on ice for 15min. After addition
of 200 μl of cold buffer D containing 20 mM Hepes at pH 7.9, 20%
glycerol, 0.2 mM EDTA, 0.5mMDTT, and 0.5mMPMSF, the suspension
was centrifuged at 12,000 ×g for 15 min at 4 °C. The supernatant was
transferred to a new tube, and the protein concentration was
measured using the Bradford protein assay reagent (Bio-Rad,
Hercules, CA) and stored at −70 °C until use. EMSA reactions were
performed by pre-incubating 5 μg of nuclear extract containing 2 μg of
poly dI–dC, 2 μg of BSA and 100 pmol of unlabeled competitor
oligonucleotide or 0.2 μg antibody where indicated, in the binding
buffer containing 10 mM Hepes at pH 7.9, 100 mM KCl, 5 mM MgCl2
and 5% glycerol on ice for 30 min. Annealed oligonucleotide probes
(2 pmol) were labeled with [γ-32P]ATP and added to the reactions.
The reactions were incubated at room temperature for 1 h, and the
complexes were resolved on 4% non-denaturing acrylamide gels.
Luciferase reporter assays
293T cells were co-transfected with 1 μg of luciferase reporter
constructs and the RTA expression vector or control vector using
SuperFect transfection reagent (Qiagen, Valencia, CA). Total DNA in
each transfection was equalized with the empty pcDNA3.1 vector.
Transfection efﬁciency was normalized by co-transfectionwith 1 μg of
the pCMV-β-gal internal control plasmid (Promega, Madison, WI).
Cells were lysed and collected 24 h post-transfection using a luciferase
assay lysis buffer (Promega). Luciferase activity was then measured
with a Veritus microplate luminometer (Turner Biosystem, Sunnyvale,
CA). All the reporter assays were carried out three times, each with
triplicates. Results are the averages of data with standard deviations
from one representative experiment.
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